查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088479

非專利吸入劑和鼻噴劑市場：按給藥途徑、患者年齡層、劑型、應用、最終用戶和分銷管道分類 - 全球市場預測（2026-2032 年）

Inhalation & Nasal Sprays Generic Drugs Market by Route Of Administration, Patient Age Group, Formulation, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，非專利吸入劑和鼻噴劑市場將成長至 183.2 億美元，複合年成長率為 9.73%。

主要市場統計數據
基準年（2025 年） 95.6億美元
預計年份（2026年） 104.2億美元
預測年份（2032年） 183.2億美元
複合年成長率（） 9.73%

介紹

非專利吸入劑和鼻噴劑用於治療氣喘、慢性阻塞性肺病（COPD）、過敏性鼻炎和急性鼻塞等令人痛苦的呼吸系統疾病和過敏性疾病。根據世界衛生組織（WHO）估計，2019年全球約有2.62億人患有氣喘，323萬人死於COPD。這凸顯了臨床上對價格合理的呼吸系統藥物的持續需求。

非專利吸入劑和鼻噴劑市場發生巨大變化。

非專利吸入劑和鼻噴劑市場正從以銷售主導的替代模式轉向以證據主導的差異化模式。美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）等監管機構繼續優先考慮生物等效性、體外性能、藥物動力學和動態證據、必要時的比較臨床終點證據以及局部呼吸道產品裝置的易用性。

人工智慧（AI）的累積影響

人工智慧 (AI) 正在對製劑開發、設備最佳化、品管、藥物安全監測和商業規劃等各個領域產生累積影響。 AI 驅動的建模能夠在進行成本高昂的實驗室重複試驗之前，評估氣溶膠顆粒行為、噴霧雲形狀、噴霧模式一致性、添加劑相互作用、沉積動力學和設備使用差異。

主要區域分析：全球需求與市場趨勢

亞太地區是重點需求中心，這得益於該地區氣喘、慢性阻塞性肺病和過敏性鼻炎患者數量龐大、都市區空氣污染嚴重、吸煙相關的呼吸系統風險以及中國和印度學名藥生產能力的不斷提升。北美仍然是監管最嚴格、商業性最重要的地區之一，美國食品藥品監督管理局（FDA）針對特定產品的指導意見、加拿大成本控制政策、支付主導替代處方藥的推廣以及對特定器械證據的期望，這些因素共同影響著非專利吸入劑和鼻噴劑的打入市場策略。

關鍵環節的考察：貿易、政策與採購環節

東協市場對非專利吸入劑和鼻噴劑的重要性日益凸顯。這是因為，儘管通用技術文件框架支持監管協調，但各國的報銷機制、註冊期限和競標規則仍存在差異。海灣合作理事會（GCC）地區的特點是集中式註冊流程、醫院採購、處方集標準化，以及公共和私人醫療機構對經濟有效的慢性呼吸系統疾病治療方案日益成長的需求。

重點國家洞察：優先學名藥市場

美國的特點是：FDA針對複雜學名藥製定了ANDA標準，學名藥使用率高，生物等效性指南針對特定產品，且監管由支付方主導。而加拿大則著重於透過省級處方藥清單和全國性的價格調整來控制醫療成本。墨西哥和巴西是拉丁美洲的主要機會國。巴西的公共醫療體系、國家法律規範以及對價格合理的慢性呼吸系統疾病治療藥物的需求，都提高了學名藥的供應。

為行業領導者提供的實用建議

產業領導者應優先考慮早期監管途徑的製定，特別是對於不同監管機構對等效性要求各異的產品，例如吸入型皮質類固醇、支氣管擴張劑、複方吸入劑、急救吸入劑和局部鼻滴鼻劑。研發專案應從一開始就整合製劑科學、器械工程、人因工程、可靠的體外測試、性能比較評估和病患使用風險評估。

分析方法

本報告採用結構化的二手研究途徑編寫，符合市場研究標準。資訊來源包括美國FDA、EMA和各國監管機構發布的監管指南，世界衛生組織（WHO）、全球過敏性疾病聯盟（GOLD）、全球過敏性疾病網路（GINA）和專門研究過敏症的科學組織提供的臨床負擔證據，以及與報銷、採購、環境衛生和基本藥物相關的政策趨勢。

結論

非專利吸入劑和鼻噴劑市場正從傳統的基於成本的替代模式，擴展到複雜的複合型學名藥領域。在這個領域，臨床等效性、設備性能、監管策略、患者便利性和供應可靠性是成功的關鍵。氣喘、慢性阻塞性肺病、過敏性鼻炎和鼻塞等疾病負擔的日益加重，凸顯了對價格合理的呼吸系統和鼻腔治療藥物的持續需求。

目錄

第1章 引言

第2章 分析方法

  • 分析設計
  • 分析框架
  • 市場規模預測
  • 數據三角測量
  • 分析結果
  • 分析的前提條件
  • 分析的局限性

第3章執行摘要

  • 首席體驗長的觀點
  • 市場規模和成長趨勢
  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入（GTM）策略

第5章 市場洞察

  • 消費者分析與最終用戶觀點
  • 消費者體驗基準測試
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第6章：人工智慧（AI）的累積影響（2026 年）

第7章：非專利吸入劑和鼻噴劑市場：依給藥途徑分類

  • 吸入
    • 乾粉吸入器
    • 定量噴霧吸入器
    • 噴霧器
    • 緩霧吸入器
  • 鼻腔

第8章：非專利吸入劑和鼻噴劑市場：依患者年齡層分類

  • 成人
  • 老年人
  • 兒童

第9章：非專利吸入劑和鼻噴劑市場：按劑型分類

  • 乾粉
  • 解決方案
  • 懸浮液

第10章：非專利吸入劑和鼻噴劑市場：按應用領域分類

  • 支氣管擴張劑
  • 組合
  • 皮質類固醇

第11章：非專利吸入劑和鼻噴劑市場：按最終用戶分類

  • 門診治療
  • 居家醫療
  • 醫院

第12章：非專利吸入劑和鼻噴劑市場：依分銷管道分類

  • 線上
  • 離線

第13章：非專利吸入劑和鼻噴劑市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：非專利吸入劑和鼻噴劑市場：按類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：非專利吸入劑和鼻噴劑市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析（2025 年）
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析（2025 年）
  • 產品系列分析（2025 年）
  • 基準分析（2025 年）

第17章：公司簡介

  • AbbVie Inc.
  • Acerus Pharmaceuticals Corporation
  • Akorn, Inc.
  • Altaire Pharmaceuticals Inc.
  • Amphastar Pharmaceuticals, Inc.
  • Apotex Inc.
  • AptarGroup, Inc.
  • AstraZeneca PLC
  • Beximco Pharmaceuticals Ltd.
  • Catalent, Inc.
  • Chiesi Farmaceutici SpA
  • Cipla Limited
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Mylan NV
  • Nephron Pharmaceuticals Corporation
  • Nippon Shinyaku Co., Ltd.
  • Padagis US LLC
  • Perrigo Company PLC
  • Preferred Pharmaceuticals, Inc.
  • Recipharm AB
  • Sandoz International GmbH
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zhejiang Xianju Pharmaceutical Co., Ltd.
Product Code: MRR-032A67D9141A

The Inhalation & Nasal Sprays Generic Drugs Market is projected to grow by USD 18.32 billion at a CAGR of 9.73% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.56 billion
Estimated Year [2026] USD 10.42 billion
Forecast Year [2032] USD 18.32 billion
CAGR (%) 9.73%

Introduction

Inhalation and nasal spray generic drugs serve high-burden respiratory and allergy indications, including asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, and acute nasal congestion. The World Health Organization reports that asthma affected an estimated 262 million people in 2019, while COPD caused 3.23 million deaths in 2019, confirming sustained clinical demand for affordable respiratory medicines.

Unlike conventional oral generics, inhaled and intranasal products are complex generics because therapeutic performance depends on the active ingredient, formulation, container-closure system, actuator, valve, pump, plume geometry, droplet or particle size distribution, delivered dose uniformity, and patient technique. This makes regulatory-quality evidence, device engineering, and manufacturing consistency central to market access and long-term competitiveness.

Transformative Shifts in Inhalation & Nasal Spray Generics

The inhalation and nasal spray generic drugs landscape is shifting from volume-led substitution toward evidence-led differentiation. Regulatory agencies such as the U.S. FDA and EMA continue to emphasize product-specific bioequivalence, in vitro performance, pharmacokinetic or pharmacodynamic evidence, comparative clinical endpoint evidence when required, and device usability for locally acting respiratory products.

At the same time, payer pressure, patent expirations, hospital formulary management, and demand for lower-cost maintenance therapy are expanding opportunities for generic inhalers and nasal sprays. Sustainability is also becoming strategic as pressurized metered-dose inhalers face scrutiny over hydrofluorocarbon propellants, accelerating interest in lower-global-warming-potential propellants, dry powder inhalers, and lifecycle-focused device decisions.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is having a cumulative impact across formulation development, device optimization, quality control, pharmacovigilance, and commercial planning. AI-enabled modeling can help evaluate aerosol particle behavior, plume geometry, spray pattern consistency, excipient interactions, deposition dynamics, and device-use variability before expensive laboratory iterations.

In manufacturing, computer vision and advanced analytics can strengthen inspection of actuators, pumps, canisters, fill volumes, crimping integrity, dose counters, and batch deviations. In the field, AI-supported adherence analytics and real-world evidence platforms can identify underuse, overuse, and inhaler technique gaps. However, AI does not replace validated bioequivalence evidence; it strengthens decision-making when governed by auditable data, model validation, cybersecurity controls, and regulatory documentation.

Key Regional Insights: Global Demand and Access Patterns

Asia-Pacific is a high-priority demand center, supported by large asthma, COPD, and allergic rhinitis populations, urban air pollution exposure, tobacco-related respiratory risk, and expanding generic manufacturing capacity in China and India. North America remains one of the most regulated and commercially significant regions, where FDA product-specific guidances, Canadian cost-containment policies, payer-led substitution, and device-specific evidence expectations shape entry strategies for inhaled and nasal complex generics.

Latin America is driven by public procurement, out-of-pocket affordability, and tender-based access, with Brazil and Mexico acting as key anchors for respiratory generic uptake. Europe benefits from harmonized quality expectations, established generic adoption, strong pharmacovigilance, and sustainability-focused inhaler policy discussions tied to healthcare decarbonization. The Middle East, particularly GCC markets, is advancing centralized procurement and branded-generic uptake as respiratory disease management gains policy attention, while Africa remains defined by access gaps, essential medicine availability, affordability constraints, and the need for reliable low-cost respiratory therapies across public and donor-supported channels.

Key Group Insights: Trade, Policy, and Procurement Blocs

ASEAN markets are increasingly important for inhalation and nasal spray generics because the ASEAN Common Technical Dossier framework supports regulatory convergence while local reimbursement, registration timelines, and tender rules remain country-specific. The GCC is shaped by centralized registration pathways, hospital procurement, formulary standardization, and growing demand for cost-effective chronic respiratory therapies across both public and private care settings.

The European Union provides scale through a mature generics framework, strong pharmacovigilance systems, reference pricing practices, and environmental policy pressure on inhaler choices. BRICS countries combine large patient populations with manufacturing depth, especially in APIs, finished dose products, and device components, while also showing diverse regulatory and access requirements. G7 markets set high evidence expectations, pricing discipline, and quality-system benchmarks that influence global development strategies. NATO is not a healthcare bloc, but its members' focus on supply resilience, stockpiling, and medical readiness is relevant for respiratory drug continuity during disruptions.

Key Country Insights: Priority Generic Drug Markets

The United States is shaped by FDA ANDA standards for complex generics, high generic utilization, product-specific bioequivalence guidances, and payer controls, while Canada emphasizes cost containment through provincial formularies and pan-Canadian pricing coordination. Mexico and Brazil are central Latin American opportunities, with Brazil's public health system, national regulatory oversight, and demand for affordable chronic respiratory medicines supporting generic access, while Mexico's public procurement reforms and pharmacy channel dynamics influence availability.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature respiratory treatment guidelines with generic substitution, reimbursement scrutiny, and environmental assessment of inhaler technologies. Russia remains a sizable market with localization considerations and demand for cost-effective respiratory therapies. In Asia-Pacific, China and India provide population scale, API and finished-dose manufacturing strength, and expanding regulatory sophistication; Japan and South Korea require high-quality regulatory evidence, device reliability, and post-market vigilance; and Australia's reimbursement system supports value-based access to clinically proven generics through evidence-driven listing and prescribing frameworks.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize early regulatory pathway mapping, especially for inhaled corticosteroids, bronchodilators, combination inhalers, rescue inhalers, and locally acting nasal sprays where equivalence requirements vary by agency. Development programs should integrate formulation science, device engineering, human factors, robust in vitro testing, comparative performance evaluation, and patient-use risk assessment from the outset.

Companies should strengthen dual sourcing for APIs, valves, pumps, canisters, propellants, excipients, dose counters, and actuators; invest in validated AI and automation for quality systems; and prepare sustainability roadmaps for propellant transitions and device lifecycle management. Commercial teams should align launches with payer evidence, prescribing guidance, patient training, substitution rules, pharmacovigilance commitments, and real-world adherence support to improve uptake and persistence.

Research Methodology

This executive summary is developed using a structured secondary-research approach aligned with market research standards. Sources include publicly available regulatory guidance from the U.S. FDA, EMA, and national authorities; clinical burden evidence from WHO, GOLD, GINA, and allergy-focused scientific bodies; and policy signals from reimbursement, procurement, environmental health, and essential medicine frameworks.

Insights are triangulated across disease burden, regulatory complexity, regional access conditions, manufacturing capabilities, quality expectations, sustainability requirements, and competitive dynamics. Only verifiable, evidence-backed themes are used, and forward-looking interpretation is limited to trends supported by observable policy, technology, regulatory, and market behavior. The analysis excludes market sizing, market share, and forecasting.

Conclusion

The inhalation and nasal spray generic drugs landscape is expanding from traditional cost-based substitution into a sophisticated complex-generics arena where clinical equivalence, device performance, regulatory strategy, patient usability, and supply reliability determine success. Growing asthma, COPD, allergic rhinitis, and nasal congestion burdens support durable demand for affordable respiratory and intranasal therapies.

Industry leaders that combine rigorous development, validated AI tools, resilient manufacturing, sustainability planning, and region-specific access strategies will be best positioned to compete. The strongest opportunities will emerge where high-quality generics reduce treatment costs while preserving therapeutic performance, device reliability, regulatory confidence, and patient trust.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Inhalation & Nasal Sprays Generic Drugs Market, by Route Of Administration

  • 7.1. Inhalation
    • 7.1.1. Dry Powder Inhaler
    • 7.1.2. Metered Dose Inhaler
    • 7.1.3. Nebulizer
    • 7.1.4. Soft Mist Inhaler
  • 7.2. Nasal

8. Inhalation & Nasal Sprays Generic Drugs Market, by Patient Age Group

  • 8.1. Adult
  • 8.2. Geriatric
  • 8.3. Pediatric

9. Inhalation & Nasal Sprays Generic Drugs Market, by Formulation

  • 9.1. Dry Powder
  • 9.2. Solution
  • 9.3. Suspension

10. Inhalation & Nasal Sprays Generic Drugs Market, by Application

  • 10.1. Bronchodilator
  • 10.2. Combination
  • 10.3. Corticosteroid

11. Inhalation & Nasal Sprays Generic Drugs Market, by End User

  • 11.1. Ambulatory Care
  • 11.2. Home Care
  • 11.3. Hospital

12. Inhalation & Nasal Sprays Generic Drugs Market, by Distribution Channel

  • 12.1. Online
  • 12.2. Offline

13. Inhalation & Nasal Sprays Generic Drugs Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Inhalation & Nasal Sprays Generic Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Inhalation & Nasal Sprays Generic Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Acerus Pharmaceuticals Corporation
  • 17.3. Akorn, Inc.
  • 17.4. Altaire Pharmaceuticals Inc.
  • 17.5. Amphastar Pharmaceuticals, Inc.
  • 17.6. Apotex Inc.
  • 17.7. AptarGroup, Inc.
  • 17.8. AstraZeneca PLC
  • 17.9. Beximco Pharmaceuticals Ltd.
  • 17.10. Catalent, Inc.
  • 17.11. Chiesi Farmaceutici S.p.A.
  • 17.12. Cipla Limited
  • 17.13. GlaxoSmithKline PLC
  • 17.14. Hikma Pharmaceuticals PLC
  • 17.15. Mylan N.V.
  • 17.16. Nephron Pharmaceuticals Corporation
  • 17.17. Nippon Shinyaku Co., Ltd.
  • 17.18. Padagis US LLC
  • 17.19. Perrigo Company PLC
  • 17.20. Preferred Pharmaceuticals, Inc.
  • 17.21. Recipharm AB
  • 17.22. Sandoz International GmbH
  • 17.23. Sanofi S.A.
  • 17.24. Sun Pharmaceutical Industries Ltd.
  • 17.25. Teva Pharmaceutical Industries Ltd.
  • 17.26. Viatris Inc.
  • 17.27. Zhejiang Xianju Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRY POWDER INHALER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRY POWDER INHALER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRY POWDER INHALER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL METERED DOSE INHALER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL METERED DOSE INHALER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL METERED DOSE INHALER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEBULIZER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEBULIZER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEBULIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SOFT MIST INHALER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SOFT MIST INHALER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SOFT MIST INHALER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NASAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NASAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NASAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRY POWDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRY POWDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRY POWDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SOLUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SOLUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SOLUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SUSPENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SUSPENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SUSPENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRONCHODILATOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRONCHODILATOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRONCHODILATOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMBINATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COMBINATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMBINATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CORTICOSTEROID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CORTICOSTEROID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CORTICOSTEROID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AMBULATORY CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AMBULATORY CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AMBULATORY CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. GCC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. GCC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. GCC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 129. GCC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GCC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 131. GCC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. GCC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. GCC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. G7 INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. G7 INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. G7 INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 153. G7 INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. G7 INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 155. G7 INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. G7 INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. G7 INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. NATO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. NATO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. NATO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 161. NATO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. NATO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 163. NATO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. NATO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. NATO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 178. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 180. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 186. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 188. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 194. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 196. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 210. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 212. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 218. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 220. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 226. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 228. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 229. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 234. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 236. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 242. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 244. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 258. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 259. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 260. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 265. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 266. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 268. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 274. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 275. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 276. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 277. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 281. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 282. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 283. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 284. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 285. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)